Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Clover Health Investments Corp’s stock clocked out at $2.88, up 3.60% from its previous closing price of $2.78. In other words, the price has increased by $3.60 from its previous closing price. On the day, 6.54 million shares were traded. CLOV stock price reached its highest trading level at $2.94 during the session, while it also had its lowest trading level at $2.7805.
Ratios:
To gain a deeper understanding of CLOV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 04 ’25 when JAMIE REYNOSO bought 6,823 shares for $2.78 per share.
Wai Conrad sold 118,600 shares of CLOV for $390,194 on Jul 22 ’25. The CEO, Counterpart Health now owns 1,494,898 shares after completing the transaction at $3.29 per share. On Jul 23 ’25, another insider, Wai Conrad, who serves as the CEO, Counterpart Health of the company, sold 91,197 shares for $3.32 each. As a result, the insider received 302,774 and left with 1,403,701 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1465681024 and an Enterprise Value of 1305584768. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.99 while its Price-to-Book (P/B) ratio in mrq is 4.12. Its current Enterprise Value per Revenue stands at 0.878 whereas that against EBITDA is -56.998.
Stock Price History:
The Beta on a monthly basis for CLOV is 1.98, which has changed by 0.5737705 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is -3.27%, while the 200-Day Moving Average is calculated to be -18.49%.
Shares Statistics:
It appears that CLOV traded 8.61M shares on average per day over the past three months and 8665240 shares per day over the past ten days. A total of 388.51M shares are outstanding, with a floating share count of 382.57M. Insiders hold about 24.83% of the company’s shares, while institutions hold 21.94% stake in the company. Shares short for CLOV as of 1752537600 were 36198932 with a Short Ratio of 4.20, compared to 1749772800 on 22280296. Therefore, it implies a Short% of Shares Outstanding of 36198932 and a Short% of Float of 8.930001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
